var irxmlnewsreleases = new Array();
irxmlnewsreleases[0]={
  "attachmentfileid":349063,
  "attachmentfilekey":"32337aca-121e-478d-984a-75a2b01450fc",
  "attachmentfilename":"VRTX_News_2010_2_4_Webcasts.pdf",
  "attachmentfilesize":35064,
  "id":1,
  "linktoreleasehtml":"http://apps.shareholder.com/irxml/irxml.aspx?CompanyID=VRTX&Format=HTML&Function=NewsReleaseDetail&Output=js2&ReleaseID=443116&PIN=9ed9f61dda2fb3f442e7e196f55bb946",
  "linktoreleasetxt":"http://apps.shareholder.com/irxml/irxml.aspx?CompanyID=VRTX&Format=TEXT&Function=NewsReleaseDetail&Output=js2&ReleaseID=443116&PIN=90006f9a73e283cd8e3251d580f19f9f",
  "releasedate":new Date(2010, 2-1, 4, 16, 4, 56),
  "releaseid":443116,
  "releasetype":"Webcasts",
  "subtitle":"<i>-HCV: New Drug Application planned for telaprevir in second half of \n\n      2010; increasing investment in commercialization and launch preparedness \n\n      activities-</i>\n\n    <br />\n\n    \n\n      <i>-CF: Development progress with two compounds in orphan disease of \n\n      cystic fibrosis; combination trial planned with VX-770 and VX-809 based \n\n      on Phase 2 data for VX-809-</i>\n\n    <br />\n\n    \n\n      <i>-Pipeline: Proof-of-concept clinical trials planned for 2010 with \n\n      novel combination regimens for hepatitis C and cystic fibrosis and with \n\n      compounds for rheumatoid arthritis and epilepsy-</i>\n\n    <br />\n\n    \n\n      <i>-Financial: Vertex enters 2010 with approximately $1.3 billion in \n\n      cash, cash equivalents and marketable securities and approximately $32 \n\n      million in outstanding 2013 convertible debt; 2010 investment to support \n\n      long-term business objectives-</i>\n\n    <br />",
  "summary":null,
  "title":"Vertex Pharmaceuticals Reports 2009 Financial Results and Highlights Recent Progress in Hepatitis C and Cystic Fibrosis Development Programs",
  "totalrecords":256,
  "year":"2010"
};
irxmlnewsreleases[1]={
  "attachmentfileid":348401,
  "attachmentfilekey":"5a6f2453-0f3f-4505-bbe9-08a1616f208a",
  "attachmentfilename":"VRTX_News_2010_2_3_Webcasts.pdf",
  "attachmentfilesize":18742,
  "id":2,
  "linktoreleasehtml":"http://apps.shareholder.com/irxml/irxml.aspx?CompanyID=VRTX&Format=HTML&Function=NewsReleaseDetail&Output=js2&ReleaseID=442429&PIN=e74784af22bd103977a2a80b95d4b7c7",
  "linktoreleasetxt":"http://apps.shareholder.com/irxml/irxml.aspx?CompanyID=VRTX&Format=TEXT&Function=NewsReleaseDetail&Output=js2&ReleaseID=442429&PIN=c635a2a6c47c86973f3d733bf1a82cc1",
  "releasedate":new Date(2010, 2-1, 3, 08, 8, 29),
  "releaseid":442429,
  "releasetype":"Webcasts",
  "subtitle":"<i>-VX-809 was well-tolerated at all dose levels when dosed once daily \n\n      for 28 days-</i>\n\n    <br />\n\n    \n\n      <i>-Statistically significant changes observed in measurement of sweat \n\n      chloride suggest increased CFTR activity-</i>\n\n    <br />\n\n    \n\n      <i>-Data support planned combination trial of VX-809 and VX-770 in \n\n      second half of 2010 for CF patients with the F508del mutation-</i>\n\n    <br />",
  "summary":null,
  "title":"Vertex Announces Results from Phase 2a Trial of VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis",
  "totalrecords":256,
  "year":"2010"
};
var IRXMLSTATUS="No Error",IRXMLSTATUSCODE="0";